Related Experiment Videos
[Toxic genetic effects of flunitrazepam]
Bollettino Della Societa Italiana Di Biologia Sperimentale
|December 30, 1984
Summary
Flunitrazepam, found in Rohypnol, shows mutagenic activity in Salmonella tests, indicating potential DNA damage. This mutagenicity extends to its urinary metabolites in both rats and humans.
Area of Science:
- Toxicology
- Genetics
- Pharmacology
Context:
- Flunitrazepam is the active ingredient in Rohypnol.
- Mutagenicity testing is crucial for assessing drug safety.
- The Salmonella/microsome assay is a standard method for detecting mutagens.
Purpose:
- To investigate the mutagenic potential of Flunitrazepam.
- To evaluate the mutagenicity of Flunitrazepam and its metabolites in biological systems.
- To determine the types of mutations induced by Flunitrazepam.
Summary:
- Flunitrazepam demonstrated a dose-related mutagenic effect on Salmonella typhimurium strain TA 100, both with and without rat liver S9 metabolic activation.
- Mutagenic activity was also detected in the urines of Flunitrazepam-treated rats and patients, using modified Salmonella tests (strains TA 98 and TA 100).
- The study suggests Flunitrazepam and/or its urinary metabolites can induce base-pair substitutions and frame-shift mutations.
Impact:
- This research highlights the genotoxic risks associated with Flunitrazepam.
- Findings contribute to understanding the safety profile of benzodiazepines.
- The study underscores the importance of evaluating drug metabolites for mutagenicity.